ArticleOncotarget2013

P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.

Rabin Said et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.